Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
14.27 USD | -2.73% | -4.23% | -34.48% |
May. 09 | Oppenheimer Adjusts Viridian Therapeutics Price Target to $31 From $36, Maintains Outperform Rating | MT |
May. 09 | B. Riley Downgrades Viridian Therapeutics to Neutral From Buy | MT |
Financials (USD)
Sales 2024 * | 370K | Sales 2025 * | 330K | Capitalization | 911M |
---|---|---|---|---|---|
Net income 2024 * | -230M | Net income 2025 * | -266M | EV / Sales 2024 * | 1,211 x |
Net cash position 2024 * | 462M | Net cash position 2025 * | 625M | EV / Sales 2025 * | 865 x |
P/E ratio 2024 * |
-3.85
x | P/E ratio 2025 * |
-3.64
x | Employees | 94 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 93.69% |
Latest transcript on Viridian Therapeutics, Inc.
1 day | -2.73% | ||
1 week | -4.23% | ||
Current month | +7.62% | ||
1 month | -8.76% | ||
3 months | -25.79% | ||
6 months | -10.70% | ||
Current year | -34.48% |
Managers | Title | Age | Since |
---|---|---|---|
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 23-10-29 |
Seth Harmon
DFI | Director of Finance/CFO | 45 | 23-04-30 |
Thomas Ciulla
CTO | Chief Tech/Sci/R&D Officer | 59 | 22-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 18-01-02 |
Tomas Kiselak
CHM | Chairman | 38 | 20-10-27 |
Stephen Mahoney
CEO | Chief Executive Officer | 53 | 23-10-29 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.06% | 234 M€ | +7.45% | - | |
0.02% | 2 M€ | -.--% | ||
0.01% | 746 M€ | -.--% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-15 | 14.27 | -2.73% | 719,140 |
24-05-14 | 14.67 | +2.30% | 640,880 |
24-05-13 | 14.34 | +3.17% | 630,499 |
24-05-10 | 13.9 | -0.07% | 858,169 |
24-05-09 | 13.91 | -6.64% | 1,729,832 |
Delayed Quote Nasdaq, May 15, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-34.48% | 911M | |
+29.77% | 49.46B | |
+1.00% | 42.58B | |
+50.47% | 42.49B | |
-5.26% | 29.09B | |
+13.68% | 26.61B | |
-22.99% | 18.64B | |
+8.22% | 13.16B | |
+32.41% | 12.55B | |
-1.62% | 11.98B |
- Stock Market
- Equities
- VRDN Stock